Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) CEO Sells $875,600.00 in Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the firm's stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $15.92, for a total transaction of $875,600.00. Following the sale, the chief executive officer owned 221,017 shares of the company's stock, valued at $3,518,590.64. This trade represents a 19.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Saurabh Saha also recently made the following trade(s):

• On Friday, June 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.63, for a total transaction of $694,650.00.
• On Tuesday, May 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.71, for a total transaction of $699,050.00.

Centessa Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ CNTA traded down $0.09 during mid-day trading on Thursday, hitting $15.48. The stock had a trading volume of 478,046 shares, compared to its average volume of 933,870. The company has a debt-to-equity ratio of 0.28, a quick ratio of 14.37 and a current ratio of 14.37. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.10 and a 1 year high of $19.09. The business has a 50 day moving average price of $13.49 and a two-hundred day moving average price of $14.42. The firm has a market cap of $2.07 billion, a P/E ratio of -8.55 and a beta of 1.45.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.15. On average, equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

Several large investors have recently added to or reduced their stakes in CNTA. GF Fund Management CO. LTD. bought a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $31,000. Caitong International Asset Management Co. Ltd boosted its holdings in Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after acquiring an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. bought a new stake in Centessa Pharmaceuticals in the first quarter valued at $47,000. Barclays PLC boosted its holdings in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Centessa Pharmaceuticals during the 1st quarter valued at $147,000. Institutional investors own 82.01% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CNTA. Truist Financial began coverage on shares of Centessa Pharmaceuticals in a research report on Monday. They set a "buy" rating and a $30.00 target price for the company. Needham & Company LLC began coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They set a "buy" rating and a $35.00 target price for the company. Guggenheim reiterated a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Oppenheimer assumed coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set an "outperform" rating and a $6.00 price target on the stock. Finally, Wall Street Zen raised shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, Centessa Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $28.10.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.